March 9, 2020 / 10:13 AM / 21 days ago

BRIEF-Kala Pharma Announces Results For Primary And Secondary Endpoints In Stride 3 Clinical Trial Evaluating Eysuvis

March 9 (Reuters) - Kala Pharmaceuticals Inc:

* KALA PHARMACEUTICALS ANNOUNCES STATISTICALLY SIGNIFICANT RESULTS FOR PRIMARY AND KEY SECONDARY ENDPOINTS IN STRIDE 3 CLINICAL TRIAL EVALUATING EYSUVIS™ FOR SIGNS AND SYMPTOMS OF DRY EYE DISEASE

* KALA PHARMACEUTICALS INC - STRIDE 3 MET BOTH PRESPECIFIED PRIMARY EFFICACY ENDPOINTS

* KALA PHARMACEUTICALS INC - STRIDE 3 MET KEY SIGN ENDPOINT OF CONJUNCTIVAL HYPEREMIA

* KALA PHARMACEUTICALS INC - STRIDE 3 CLINICAL TRIAL DATA ENABLES EYSUVIS NDA RESUBMISSION IN 2Q 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below